Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1,644,695
-
Total 13F shares
-
18,925,568
-
Share change
-
-108,765
-
Total reported value
-
$38,103,347
-
Put/Call ratio
-
12%
-
Price per share
-
$2.01
-
Number of holders
-
30
-
Value change
-
-$235,866
-
Number of buys
-
7
-
Number of sells
-
9
Institutional Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q1 2023
As of 31 Mar 2023,
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,925,568 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, Nantahala Capital Management, LLC, PURA VIDA INVESTMENTS, LLC, Samsara BioCapital, LLC, VR Adviser, LLC, VANGUARD GROUP INC, Soleus Capital Management, L.P., Ikarian Capital, LLC, Ensign Peak Advisors, Inc, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
30
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.